Using functional near-infrared spectroscopy to study effects of virtual reality intervention for adolescents with depression in a clinical setting in China: study protocol for a prospective, randomised, controlled trial
Kunqiang Yu,Lijun Wang,Shiqiao Lv,Xiaofang Ye,Linhui Liu,Xiuxiu Zheng,Ruomei Jin,Dongsheng Zhou,Yan Zhang,Guoqing Min,Shaochang Wu,Yu,K.,Wang,L.,Lv,S.,Ye,X.,Liu,L.,Zheng,X.,Jin,R.,Zhou,D.,Zhang,Y.,Min,G.,Wu,S.
DOI: https://doi.org/10.1136/bmjopen-2023-074129
IF: 3.006
2023-12-16
BMJ Open
Abstract:Introduction Adolescent depression has been shown to be associated with many devastating psychosocial outcomes. However, there are many barriers that may prevent depressed individuals from receiving specialised treatment. Virtual reality (VR) technology has shown promise as one avenue for overcoming these challenges. This study first aims to evaluate the effectiveness of VR intervention on adolescent depression symptoms, and second, to determine the intervention's underlying mechanism of effect using functional near-infrared spectroscopy (fNIRS). Methods and analysis This is a single-centre, prospective, randomised controlled clinical trial. Sixty-six eligible adolescents aged 12–18 years with a diagnosis of depression will be randomised in a 1:1 ratio to either the VR treatment group or the conventional treatment group. All patients for both groups will receive usual treatment during a 4-week intervention period. In addition, patients randomised to VR treatment group (n=33) will complete three 20 min VR sessions including attention, executive function and relaxation training per week. Moreover, 33 healthy adolescents will be recruited as the general population. Primary outcome (ie, depressive symptoms) and secondary outcomes (ie, anxiety symptoms, executive function, treatment emergent symptoms, haemoglobin changes measured by fNIRS) will be collected at preintervention, immediately postintervention and at 4 weeks follow-up. The data assessor and analyst will be blinded to group membership. Ethics and dissemination Ethical approval has been obtained from the Ethics Committee of Lishui Second People's Hospital. Written informed consent will be obtained for all participants. Results will be disseminated through peer-reviewed journals, national or international conference presentations, media outlets, the internet and various community activities. Trial registration number ChiCTR2300067747.
medicine, general & internal